Galmed Pharmaceuticals Net Worth
Galmed Pharmaceuticals Net Worth Breakdown | GLMD |
Galmed Pharmaceuticals Net Worth Analysis
Galmed Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Galmed Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Galmed Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Galmed Pharmaceuticals' net worth analysis. One common approach is to calculate Galmed Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Galmed Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Galmed Pharmaceuticals' net worth. This approach calculates the present value of Galmed Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Galmed Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Galmed Pharmaceuticals' net worth. This involves comparing Galmed Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Galmed Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Galmed Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Galmed Pharmaceuticals' net worth research are outlined below:
| Galmed Pharmaceuticals is way too risky over 90 days horizon | |
| Galmed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Galmed Pharmaceuticals Stock Crosses Below 200 Day Moving Average Time to Sell |
Galmed Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Galmed Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Galmed Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Galmed Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Galmed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Galmed Pharmaceuticals backward and forwards among themselves. Galmed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Galmed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Zrc Wealth Management, Llc | 2024-09-30 | 1.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Advisers, Llc | 2024-06-30 | 0.0 | Walleye Trading Advisors, Llc | 2024-06-30 | 290.6 K | Cvi Holdings Llc | 2024-06-30 | 47.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 36.2 K | Susquehanna International Group, Llp | 2024-06-30 | 11.6 K | Two Sigma Securities, Llc | 2024-06-30 | 10.3 K | Ubs Group Ag | 2024-06-30 | 280 | Wells Fargo & Co | 2024-06-30 | 204 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 167 |
Follow Galmed Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.76 M.Market Cap |
|
Project Galmed Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | 0.54 | 0.57 | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.50) | (0.47) |
When accessing Galmed Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Galmed Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Galmed Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Galmed Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galmed Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Galmed Pharmaceuticals' management manipulating its earnings.
Evaluate Galmed Pharmaceuticals' management efficiency
Galmed Pharmaceuticals has return on total asset (ROA) of (0.2931) % which means that it has lost $0.2931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5267) %, meaning that it created substantial loss on money invested by shareholders. Galmed Pharmaceuticals' management efficiency ratios could be used to measure how well Galmed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.57, whereas Return On Tangible Assets are forecasted to decline to (0.44). At present, Galmed Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 9.93, whereas Other Current Assets are forecasted to decline to about 410.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 60.34 | 63.36 | |
| Tangible Book Value Per Share | 60.34 | 63.36 | |
| Enterprise Value Over EBITDA | 0.23 | 0.25 | |
| Price Book Value Ratio | 0.09 | 0.09 | |
| Enterprise Value Multiple | 0.23 | 0.25 | |
| Price Fair Value | 0.09 | 0.09 | |
| Enterprise Value | 171.1 M | 162.6 M |
Galmed Pharmaceuticals has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Return On Equity (0.53) |
Galmed Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 28th of October 2024 Other Reports | ViewVerify | |
6K | 21st of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 20th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Galmed Pharmaceuticals Earnings per Share Projection vs Actual
Galmed Pharmaceuticals Corporate Management
| Shani Ganon | Human Manager | Profile | |
| Tali Gorfine | Medical Consultant | Profile | |
| Yael Hollander | Vice Strategy | Profile | |
| Guy Nehemya | COO Officer | Profile | |
| Niv Alon | Head PMO | Profile | |
| Doron Cohen | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.